Although KRAS mutation confers a status of greater resistance to chemotherapy treatment, patients who do not have the mutation (WT-KRAS) have a longer survival based on two principles as follows: (1) greater effect of chemotherapy; and (2) addition of a biological agent that causes a better tumor response. This evidence concerns the gene KRAS and neoplasm.